Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
about
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancerMetabolic complications of androgen deprivation therapy for prostate cancerGonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysisOptimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysisAdverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complicationsProstate cancer: ESMO Consensus Conference Guidelines 2012Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapyLong-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate CancerClinical significance of androgen secretion disorders in men with a malignancy.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Radiation therapy in prostate cancer: a risk-adapted strategy.Cardiac and cognitive effects of androgen deprivation therapy: are they real?Contemporary role of androgen deprivation therapy for prostate cancerAndrogen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.Update on the management of prostate cancer with goserelin acetate: patient perspectivesBone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyAndrogen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Clinical management and burden of prostate cancer: a Markov Monte Carlo model.Cardiovascular risk during hormonal treatment in patients with prostate cancer.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksMetabolic effects of androgen deprivation therapyDiabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.Androgen deprivation therapy and cardiovascular risk.An update on the changing indications for androgen deprivation therapy for prostate cancer.Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Radiation treatment for patients with intermediate-risk prostate cancer.An update on androgen deprivation therapy for prostate cancer.Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancerCardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studiesProstate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.Impact of androgen deprivation therapy on cardiovascular disease and diabetes.Emerging cardiometabolic complications of androgen deprivation therapy.Androgen regulation of prostate cancer: where are we now?Triptorelin in the management of prostate cancer.Challenges of managing elderly men with prostate cancer.
P2860
Q24193722-61A839DA-6450-4AE6-81AE-919B357FF096Q24616159-26D90465-1791-42B9-AF20-C6113F71B559Q26777150-07948763-F355-4BB1-9F84-AE9A9C0E98BAQ26801000-F51F871A-DE52-4C47-9C69-804E49D4E153Q26852930-3887AB53-4D8B-4621-97AA-93DFD320737DQ27022847-B0B14731-05F4-4111-85BD-353CD57B5A1FQ27308917-ECA74B03-468F-475B-BBA5-867C4D8725BBQ33819775-DCFFFDF3-30E8-4315-B43D-DE06D7D021F0Q33840617-5A406DE7-F601-4BD6-993C-792FF6906FC0Q33977523-689054D4-4C5C-412F-A598-78F25665ABA8Q34111590-5A63FC93-DCBA-4D1D-8D67-17742BD13A55Q34111628-4D779AF8-C029-477D-84D5-6D40FB72D070Q34211155-2E32CD65-3213-47C4-B6A1-0345DC7091AFQ34267991-DC1B3E9B-ED15-470E-A9A8-EF198DDFD881Q34418403-0A404EBB-8056-4CDD-8B9E-22E03806411FQ34490592-6FB235FF-F910-4034-8A76-C34D3EA14C48Q34505196-97F048EC-4FF9-42C8-86F0-4CEC2794018BQ34617924-89E6AF6F-CD38-4E98-A099-AAEBFF6B1039Q34634410-99855352-41BE-4855-A8A6-38E25935554EQ34721165-F991B066-2AD9-43E7-9394-FD3B336EF61DQ34960686-E9107331-1EBA-44A3-BB36-5549F6B9C189Q34962416-F5D82938-EECB-4F9E-8020-9CB4C8817CC8Q35022837-A1E61142-7F98-45DF-9E47-AD6E3FE11768Q35229730-E248AC99-F332-4C2D-BE3A-D503A6FBF172Q35549863-4466DE4E-C99C-4CDD-9C86-0F5155334688Q35689824-7C608E2C-FA64-4F80-90D4-E6FC19CB58F9Q35992830-483B487E-FFF6-4CCA-8AC5-CE987D159D0DQ36289952-40D18756-6741-46C8-A886-4F53236421D3Q36668905-605FE23D-B5B5-4526-B046-18533724ED7EQ36690539-89C40736-66CB-44B3-A2AC-651FCC78E936Q36898849-8F055C2F-8E3A-49D2-8DF9-5A23E4CA1C77Q37103095-CD457BCE-F39D-4BD2-A60C-0F4239D99A00Q37205661-FC028587-18A1-40E2-AF70-5A2B0DDDECBFQ37390104-BCB36407-C285-482A-B2DE-61B989728D4EQ37431937-A9925F5A-524F-41B1-B219-610276419DFCQ37583719-C1651985-66A4-4DED-83C4-5A37AF970509Q37690775-5C33A415-9BCB-4F1E-BE86-2156724E854EQ37836264-7DF218C4-6451-408C-904E-F71616E9E4A2Q38068495-265667B7-9E89-46B9-84BA-BC7F0101D396Q38211358-48C30F21-0638-4F3E-8407-8D32068F1C83
P2860
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Cardiovascular mortality and d ...... ancer: analysis of RTOG 92-02.
@en
Cardiovascular mortality and d ...... ancer: analysis of RTOG 92-02.
@nl
type
label
Cardiovascular mortality and d ...... ancer: analysis of RTOG 92-02.
@en
Cardiovascular mortality and d ...... ancer: analysis of RTOG 92-02.
@nl
prefLabel
Cardiovascular mortality and d ...... ancer: analysis of RTOG 92-02.
@en
Cardiovascular mortality and d ...... ancer: analysis of RTOG 92-02.
@nl
P2093
P1433
P1476
Cardiovascular mortality and d ...... ancer: analysis of RTOG 92-02.
@en
P2093
Gerald E Hanks
Howard M Sandler
Jason A Efstathiou
Kyounghwa Bae
Matthew R Smith
Miljenko V Pilepich
William U Shipley
P304
P356
10.1016/J.EURURO.2008.01.021
P407
P577
2008-01-15T00:00:00Z